Article

Vitamin D May Reduce Fibromyalgia Pain

Author(s):

A small study found that patients with severe pain and fibromyalgia syndrome reported a marked reduction in pain with the cholecalciferol supplementation.

A small Austrian study of patients with severe pain and fibromyalgia syndrome (FMS) suggests that supplementation with cholecalciferol was effective in reducing pain. Researchers concluded that this economical therapy with a low side-effect profile may be helpful in patients with FMS. The study was published in February 2014 Pain.

In the trial, 30 women with FMS, who had serum cholecalciferol levels below 32 mg/mL, were randomized to treatment or control groups. The goal was to achieve serum cholecalciferol levels between 32 and 48 mg/mL for 20 through oral supplementation with cholecalciferol. Reevaluation was performed in both groups after a further 24 weeks without cholecalciferol supplementation.

Pain was evaluated on several scales and questionnaires, including a visual analog scale, the Short Form Health Survey 36, Hospital Anxiety and Depression Scale, and the Fibromyalgia Impact Questionnaire.

Investigators reported a marked reduction in pain over the treatment period in the group that received the cholecalciferol supplementation. The pain reduction was significant as rated on the visual analog scale scores, which correlated with scores on the physical role functioning scale of the Short Form Health Survey 36. Furthermore, optimization of calcifediol in FMS had a positive effect on the pain perception.

Further studies of larger number of patients are needed, but the researchers said cholecalciferol may well be considered in patients with FMS.

Related Videos
Orrin Troum, MD: Accurately Imaging Gout With DECT Scanning
John Stone, MD, MPH: Continuing Progress With IgG4-Related Disease Research
Philip Conaghan, MBBS, PhD: Investigating NT3 Inhibition for Improving Osteoarthritis
Rheumatologists Recognize the Need to Create Pediatric Enthesitis Scoring Tool
Presence of Diffuse Cutaneous Disease Linked to Worse HRQOL in Systematic Sclerosis
Alexei Grom, MD: Exploring Safer Treatment Options for Refractory Macrophage Activation Syndrome
Jack Arnold, MBBS, clinical research fellow, University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine
John Tesser, MD, Adjunct Assistant Professor of Medicine, Midwestern University, and Arizona College of Osteopathic Medicine, and Lecturer, University of Arizona Health Sciences Center, and Arizona Arthritis & Rheumatology Associates
Gaith Noaiseh, MD: Nipocalimab Improves Disease Measures, Reduces Autoantibodies in Sjogren’s
Laure Gossec, MD, PhD: Informing Physician Treatment Choices for Psoriatic Arthritis
© 2024 MJH Life Sciences

All rights reserved.